Janet Dancey
Janet Dancey
Unknown affiliation
No verified email
TitleCited byYear
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
EA Eisenhauer, P Therasse, J Bogaerts, LH Schwartz, D Sargent, R Ford, ...
European journal of cancer 45 (2), 228-247, 2009
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
FA Shepherd, J Dancey, R Ramlau, K Mattson, R Gralla, M O'Rourke, ...
Journal of Clinical Oncology 18 (10), 2095-2103, 2000
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
RC Coombes, E Hall, LJ Gibson, R Paridaens, J Jassem, T Delozier, ...
New England Journal of Medicine 350 (11), 1081-1092, 2004
Phase II trial of gefitinib in recurrent glioblastoma
JN Rich, DA Reardon, T Peery, JM Dowell, JA Quinn, KL Penne, ...
Journal of Clinical Oncology 22 (1), 133-142, 2004
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study
E Galanis, JC Buckner, MJ Maurer, JI Kreisberg, K Ballman, J Boni, ...
Journal of Clinical Oncology 23 (23), 5294-5304, 2005
Issues and progress with protein kinase inhibitors for cancer treatment
J Dancey, EA Sausville
Nature reviews Drug discovery 2 (4), 296, 2003
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
SM Chang, P Wen, T Cloughesy, H Greenberg, D Schiff, C Conrad, K Fink, ...
Investigational new drugs 23 (4), 357-361, 2005
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of …
MJ Moore, J Hamm, J Dancey, PD Eisenberg, M Dagenais, A Fields, ...
Journal of clinical oncology 21 (17), 3296-3302, 2003
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
MB Thomas, R Chadha, K Glover, X Wang, J Morris, T Brown, A Rashid, ...
Cancer 110 (5), 1059-1067, 2007
Strategies for optimizing combinations of molecularly targeted anticancer agents
JE Dancey, HX Chen
Nature reviews Drug discovery 5 (8), 649, 2006
mTOR signaling and drug development in cancer
J Dancey
Nature reviews Clinical oncology 7 (4), 209, 2010
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
I Duran, J Kortmansky, D Singh, H Hirte, W Kocha, G Goss, L Le, A Oza, ...
British journal of cancer 95 (9), 1148, 2006
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
L Seymour, J Bogaerts, A Perrone, R Ford, LH Schwartz, S Mandrekar, ...
The Lancet Oncology 18 (3), e143-e152, 2017
Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres
JE Dancey, FA Shepherd, K Paul, KW Sniderman, S Houle, J Gabrys, ...
Journal of nuclear medicine 41 (10), 1673-1681, 2000
Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study
JJ Rusthoven, E Eisenhauer, C Butts, R Gregg, J Dancey, B Fisher, ...
Journal of clinical oncology 17 (4), 1194-1199, 1999
Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy
J Dancey, B Zee, D Osoba, M Whitehead, F Lu, L Kaizer, J Latreille, ...
Quality of life research 6 (2), 0-0, 1997
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
EEW Cohen, DW Davis, TG Karrison, TY Seiwert, SJ Wong, S Nattam, ...
The lancet oncology 10 (3), 247-257, 2009
Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group
AM Oza, L Elit, MS Tsao, S Kamel-Reid, J Biagi, DM Provencher, ...
Journal of Clinical Oncology 29 (24), 3278, 2011
The genetic basis for cancer treatment decisions
JE Dancey, PL Bedard, N Onetto, TJ Hudson
Cell 148 (3), 409-420, 2012
Targeting epidermal growth factor receptor—are we missing the mark?
JE Dancey, B Freidlin
The Lancet 362 (9377), 62-64, 2003
The system can't perform the operation now. Try again later.
Articles 1–20